Volume 17, Number 12—December 2011
Q Fever in Woolsorters, Belgium
Highlight and copy the desired format.
|EID||Wattiau P, Boldisova E, Toman R, Van Esbroeck M, Quoilin S, Hammadi S, et al. Q Fever in Woolsorters, Belgium. Emerg Infect Dis. 2011;17(12):2368-2369. https://dx.doi.org/10.3201/eid1712.101786|
|AMA||Wattiau P, Boldisova E, Toman R, et al. Q Fever in Woolsorters, Belgium. Emerging Infectious Diseases. 2011;17(12):2368-2369. doi:10.3201/eid1712.101786.|
|APA||Wattiau, P., Boldisova, E., Toman, R., Van Esbroeck, M., Quoilin, S., Hammadi, S....Fretin, D. (2011). Q Fever in Woolsorters, Belgium. Emerging Infectious Diseases, 17(12), 2368-2369. https://dx.doi.org/10.3201/eid1712.101786.|
To the Editor: Recent outbreaks of Q fever in the Netherlands and the United Kingdom raised public awareness about this ubiquitous bacterial disease known for decades to circulate worldwide (1–4). The disease, which ranges from a self-recovering influenza-like illness to pneumonia and severe meningoencephalitis, myocarditis, or endocarditis, is usually transmitted from animals to humans by airborne particles derived from contaminated feces and birth products. Clinical symptoms develop in only ≈40% of infected humans (1). In ≈1%–2% of these persons, symptoms evolve toward the chronic form of the disease, which can be life-threatening (5).
Q fever seroprevalence in the general population in Europe ranges from 2.4% to >30% in some countries in the Mediterranean region (5). Despite improved awareness during the past 3 years and geographic proximity with the Netherlands, few human cases were reported in Belgium (14, 27, and 33 cases in 2007, 2008, and 2009, respectively) (6). A retrospective survey of blood donors in the Netherlands showed a seroprevalence of 2.4% before the start of outbreaks (7). In France, the prevalence of the disease in the Nord-Pas-de-Calais region bordering Belgium is low and accounts for only 0.5% of Q fever cases in France (8). Seroprevalence of the general population in Belgium, although unknown, is thus probably comparable with that in neighboring countries in absence of outbreaks and is not expected to exceed 5%.
We report a serologic, epidemiologic, and microbiological Q fever survey conducted in a scouring factory that processed wool and goat hair products in Belgium. No acute Q fever episodes were previously reported by the factory workers. Data on clinical symptoms and risk factors were obtained in face-to-face interviews, and associations with seropositivity were explored by using regression analysis. Airborne dust collected inside the factory during goat hair processing (9) contained 102–103 genome equivalents of Coxiella burnetii, the Q fever agent, per liter of air as estimated by real-time PCR (Laboratoire Service International, Lissieu, France) (Table A1). Sheep wool processing generated less dust and resulted in a C. burnetii air load that never reached 10 genome equivalents/L in our analyses. No information is available about the infectivity or viability of air-suspended C. burnetii in the studied environment.
Q fever serologic analysis was conducted by using an in-house ELISA for serum samples from 69 workers obtained annually during 2007–2009. Results of samples from the third year were confirmed in parallel by using an immunofluorescent assay (IFA) (Focus Diagnostics, Cypress, CA, USA) in the reference laboratory in Belgium and with follow-up samples in cases of noninterpretable or suspected serologic profiles. The 3-year cumulative seroprevalence was 50.7% (Table). This high value likely results from occupational exposure inside the factory. However, one cannot exclude that characteristics such as traveling abroad, farming, or living near farm animals might account for part of the seroprevalence. Nevertheless, such characteristics could not be associated with positive serologic results in our epidemiologic analysis.
The serologic status of 2 workers (T3 and T42) was compatible with ongoing chronic Q fever as assessed by IFA and ELISA (Table). Another IFA conducted in the reference laboratory in France confirmed a serologic status compatible with chronic Q fever for worker T3 and detected anti–phase I and II IgA in this worker. However, chronic status was not confirmed for worker T42 by this laboratory (Table A1).
Profiles of other workers in the cohort were characterized by increased anti–phase II IgG, IgM, or both (9/69, 13%) over a 2-year period. These profiles suggest relapse and may result from continuous exposure to the Q fever agent, which led to reinfection or repeated stimulation of the immune response. Molecular testing did not detect C. burnetii DNA in any blood sample, and clinical examinations did not detect endocarditis in worker T3 as analyzed by positron emission tomography and transthoracic and transesophagian echocardiography. However, infection of tissues other than the heart in this worker cannot be ruled out.
Our results indicate high seroprevalence of Q fever among workers at the scouring factory studied. Continuous exposure to the Q fever agent was the likely cause of atypical antibody responses evoking a chronic or relapsing disease in the absence of any clinical symptom. These results indicated the need to analyze paired serum samples and to rely on medical follow-up before establishing a definitive diagnosis.
Given the continuous occupational risk to which these workers are exposed, hiring of pregnant women or persons with underlying medical conditions, such as valvulopathy or immunologic depression, should be avoided. Moreover, annual serologic testing should be conducted on all exposed persons to detect any evolution toward the chronic form of the disease, which can be life-threatening. Although less dangerous than anthrax, Q fever is still a highly prevalent occupational disease that affects persons working with animal hairs in industrial environments and commonly referred to as woolsorters (10).
We thank the factory workers for participating in the study and S. Malbrecq for assistance with real-time PCRs.
This study was supported by the Occupational Medicine group Provikmo, the Veterinary and Agro-chemical Research Centre, the Slovak Ministry of Education (grant no. 2/0127/10), and the Slovak Academy of Sciences.
- Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12:518–53.
- Schimmer B, Morroy G, Dijkstra F, Schneeberger PM, Weers-Pothoff G, Timen A, Large ongoing Q fever outbreak in the south of the Netherlands, 2008. Euro Surveill. 2008;13. pi: 18939.
- Wallensten A, Moore P, Webster H, Johnson C, van der Burgt G, Pritchard G, Q fever outbreak in Cheltenham, United Kingdom, in 2007 and the use of dispersion modelling to investigate the possibility of airborne spread. Euro Surveill. 2010; 15. pii: 19521.
- Wilson LE, Couper S, Prempeh H, Young D, Pollock KG, Stewart WC, Investigation of a Q fever outbreak in a Scottish co-located slaughterhouse and cutting plant. Zoonoses Public Health. 2010;57:493–8.
- European Centre for Disease Prevention and Control. Risk assessment on Q fever, 2010 [cited 2011 Jun 16]. http://www.ecdc.europa.eu/en/publications/Publications/1005_TER_Risk_Assessment_Qfever.pdf
- Working Group on Foodborne Infections and Intoxications. Trends and sources. Report on zoonotic agents in Belgium, 2011 [cited 2011 Jun 16]. http://www.afsca.be/publicationsthematiques/_documents/2008-2009_Report-on-zoonotic-agents_en.pdf
- Schimmer B, Notermans DW, Harms MG, Reimerink JH, Bakker J, Schneeberger P, Low seroprevalence of Q fever in the Netherlands prior to a series of large outbreaks. Epidemiol Infect. 2011;▪▪▪:1–9 .
- Frankel D, Richet H, Renvoisé E, Raoult D. Q fever in France, 1985–2009. Emerg Infect Dis. 2011;17:350–6.
- Wattiau P, Klee SR, Fretin D, Van Hessche M, Menart M, Franz T, Occurrence and genetic diversity of Bacillus anthracis strains isolated in an active wool-cleaning factory. Appl Environ Microbiol. 2008;74:4005–11.
- Wattiau P, Govaerts M, Frangoulidis D, Fretin D, Kissling E, Van Hessche M, Immunologic response of unvaccinated workers exposed to anthrax, Belgium. Emerg Infect Dis. 2009;15:1637–40.
- Table. Serologic results for Q fever in woolsorters, Belgium, 2007–2009
- Table A1. Coxiella burnetii TaqVet quantitative real-time PCR kit results, Belgium, 2007–2009
Please use the form below to submit correspondence to the authors or contact them at the following address:
Pierre Wattiau, Veterinary and Agrochemical Research Centre, Bacterial Diseases, Groeselenbergstr. 99, Brussels B-1180, Belgium
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: November 18, 2011
- Page last updated: November 18, 2011
- Page last reviewed: November 18, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)